Probucol inhibits oxidative modification of low density lipoprotein.
Open Access
- 1 February 1986
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 77 (2) , 641-644
- https://doi.org/10.1172/jci112349
Abstract
Previous studies have established that low density lipoprotein (LDL) incubated with endothelial cells (EC) undergoes extensive oxidative modification in structure and that the modified LDL is specifically recognized by the acetyl LDL receptor of the macrophage. Thus, in principle, EC-modified LDL could contribute to foam cell formation during atherogenesis. Oxidatively modified LDL is also potentially toxic to EC. The present studies show that addition of probucol during the incubation of LDL with EC prevents the increase in the electrophoretic mobility, the increase in peroxides, and the increase in subsequent susceptibility to macrophage degradation. It has also been shown that oxidation of LDL catalyzed by cupric ion induces many of the same changes occurring during EC modification. Addition of probucol (5 microM) also prevented this copper-catalyzed modification of LDL. Most importantly, samples of LDL isolated from plasma of hypercholesterolemic patients under treatment with conventional dosages of probucol were shown to be highly resistant to oxidative modification either by incubation with endothelial cells or by cupric ion in the absence of cells. The findings suggest the hypothetical but intriguing possibility that probucol, in addition to its recognized effects on plasma LDL levels, may inhibit atherogenesis by limiting oxidative LDL modification and thus foam cell formation and/or EC injury. Other compounds with antioxidant properties might behave similarly.This publication has 23 references indexed in Scilit:
- Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein.Proceedings of the National Academy of Sciences, 1985
- A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit.Journal of Lipid Research, 1984
- Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins.Proceedings of the National Academy of Sciences, 1981
- THE ROLE OF THE MONOCYTE IN ATHEROGENESIS .1. TRANSITION OF BLOOD-BORNE MONOCYTES INTO FOAM CELLS IN FATTY LESIONS1981
- Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophagesProceedings of the National Academy of Sciences, 1980
- Altered Metabolism (In Vivo and In Vitro) of Plasma Lipoproteins after Selective Chemical Modification of Lysine Residues of the ApoproteinsJournal of Clinical Investigation, 1979
- LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in cultureAtherosclerosis, 1979
- Oxygen-mediated heterogeneity of apo-low-density lipoprotein.Proceedings of the National Academy of Sciences, 1978
- Influence of 4,4'-(Isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on Experimental Atherosclerosis in RabbitsExperimental Biology and Medicine, 1971
- STUDIES ON THE ROLE OF LIPOPEROXIDES IN HUMAN PATHOLOGYActa Pathologica Microbiologica Scandinavica, 1952